This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Tim Wilsdon moderates the session discussing how to fast-track policy solutions that could address the barriers preventing patient access to NGS and identify the ones that should be prioritized.
For more information on this event, click here.
CRA Life Sciences continues its series on leveraging RADAR, an orphan drug data repository. With rare oncology diseases in the spotlight at ASCO this season,...
Radioligand therapies (RLTs) are poised to transform the oncology treatment paradigm and transition to more mainstream treatment in oncology. Recent commercial...
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
